预约演示
更新于：2025-11-17
Vortioxetine Hydrobromide
氢溴酸伏硫西汀
更新于：2025-11-17
概要
基本信息
药物类型 小分子化药 |
别名 1-[2-(2,4-Dimethylphenylsulfanyl)phenyl]piperazine monohydrobromide、VORTIOXETINE、Vortioxetine hydrobromide (JAN/USAN) + [17] |
作用方式 激动剂、拮抗剂、抑制剂 |
作用机制 5-HT1A receptor激动剂(5-羟色胺1A受体激动剂)、5-HT1B receptor激动剂(5-羟色胺1B受体激动剂)、5-HT1D receptor拮抗剂(5-羟色胺1D受体拮抗剂) |
原研机构 |
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (2013-09-30), |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C18H23BrN2S |
InChIKeyVNGRUFUIHGGOOM-UHFFFAOYSA-N |
CAS号960203-27-4 |
关联
180
项与 氢溴酸伏硫西汀 相关的临床试验NCT07204314
A Randomized, Double-blind, Placebo-Controlled Phase 3 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Once-Daily Oral Administration of Vortioxetine in Japanese Pediatric Patients 12 to 17 Years of Age With Major Depressive Disorder (MDD)
TCTR20250108005
A Bioequivalence study of a randomized, open-label, single dose, two-way crossover design with two-period, two-treatment and two-sequence of Vortioxetine Film-coated Tablet 10 mg relative to Brintellix 10 mg in healthy Thai volunteers under fasting condition
CTRI/2024/09/073258
To assess the safety, effectiveness and utility of vortioxetine as initial line therapy in the Management of depression through an observational, multicenter Study - IMPRESS
100 项与 氢溴酸伏硫西汀 相关的临床结果
登录后查看更多信息
100 项与 氢溴酸伏硫西汀 相关的转化医学
登录后查看更多信息
100 项与 氢溴酸伏硫西汀 相关的专利（医药）
登录后查看更多信息
1,000
项与 氢溴酸伏硫西汀 相关的文献（医药）2025-12-01JOURNAL OF MOLECULAR HISTOLOGY
Vortioxetine protects against methotrexate-induced ovarian toxicity through anti-inflammatory, antioxidant and antiapoptotic pathways: a multi-marker immunohistochemical study
Article
作者: Ozcan, Kadriye Nilay ; Sarman, Emine ; Nazıroglu, Irem ; Asci, Halil ; Kolay, Oznur
AIMS:
Methotrexate (MTX), a commonly used chemotherapeutic and immunosuppressive agent, is known to induce significant ovarian toxicity through mechanisms involving oxidative stress, inflammation, and apoptosis. Vortioxetine (VTX), a novel antidepressant with proven neuroprotective and anti-inflammatory properties, has not yet been evaluated in the context of chemotherapy-induced gonadotoxicity. This study aimed to investigate the protective effects of VTX against MTX-induced ovarian injury in a rat model by employing comprehensive histopathological and immunohistochemical evaluations.
METHODS AND RESULTS:
Thirty-two adult female Wistar Albino rats (300-350 g) were randomly divided into four equal groups (n = 8): Control, MTX, MTX + VTX, and VTX. Ovarian damage was induced with a single intraperitoneal injection of MTX (20 mg/kg), while VTX was administered daily (10 mg/kg) by oral gavage for five days. Rats were sacrificed on day 5, and bilateral ovaries were collected. Histopathological evaluation included follicular degeneration, vascular congestion, hemorrhage, and inflammatory cell infiltration. Immunohistochemical analyses were performed for 8-Hydroxy-2'-deoxyguanosine (8-OHdG), nuclear factor kappa B (NF-κB), tumor necrosis factor-alpha (TNF-α), caspase 3 (Cas-3), and Anti-Müllerian hormone (AMH) to assess oxidative stress, inflammation, apoptosis, and ovarian reserve. MTX administration caused severe follicular atresia, hemorrhage, and dense neutrophil infiltration. Immunohistochemically, 8-OHdG, NF-κB, TNF-α, and Cas-3 expressions were significantly elevated, while AMH was markedly reduced. VTX co-treatment significantly attenuated histological damage and modulated the expression of all biomarkers, indicating potent protective effects. VTX alone did not induce deleterious changes.
CONCLUSION:
VTX exhibits a robust protective effect against MTX-induced ovarian injury via suppression of oxidative stress, inflammatory response and apoptotic pathways, while simultaneously preserving ovarian reserve. These findings highlight a novel application for VTX in fertility preservation strategies during chemotherapeutic interventions.
2025-12-01PSYCHIATRY RESEARCH
Investigation of the effects of vortioxetine and duloxetine on cognitive functions in major depressive disorder: an 8-week prospective study
作者: Çoban, Cansu ; Bulut, Süheyla Doğan
BACKGROUND:
Major depressive disorder (MDD) is a prevalent psychiatric condition characterized by cognitive deficits-including impairments in attention, memory, and executive functions-that persist during both acute episodes and remission. These cognitive deficits contribute to significant functional impairment and increase the risk of relapse. This study aimed to investigate the effects of duloxetine and vortioxetine, two antidepressants with distinct mechanisms of action, on cognitive functions in patients with MDD.
METHODS:
In this 8-week prospective study, 103 participants were enrolled: 35 patients with MDD treated with vortioxetine (10-20 mg), 34 with duloxetine (60-90 mg), and 34 healthy controls. Depressive symptom severity and clinical features were assessed using the Hamilton Depression Rating Scale, Hamilton Anxiety Rating Scale, and Clinical Global Impression Scale. Cognitive functions were evaluated with the Stroop TBAG form, Trail Making Test, and Auditory Verbal Learning Test.
RESULTS:
During the acute phase, patients with MDD performed significantly worse than healthy controls on tests of attention, processing speed, memory, and executive functions. After eight weeks of treatment, cognitive functions improved in both the duloxetine and vortioxetine groups. Vortioxetine was associated with greater improvements in selective and sustained attention and executive functions compared to duloxetine.
CONCLUSION:
Residual symptoms persisting during remission may be attributable to ongoing cognitive deficits. Addressing cognitive dysfunction is crucial for restoring functional capacity and preventing relapse in MDD. Further research with larger sample sizes is warranted to inform optimal treatment strategies.
2025-10-01NEUROSCIENCE
A review of the TGF-β1 pathway in Alzheimer’s disease and depression: Possible restoration potential of antidepressants
Review
作者: Eleni, Ioannidou ; Zisis, Bourtzos ; Theofanis, Vavilis ; Eleni, Stamoula
Alzheimer's Disease (AD), the most common type of dementia, is increasing rapidly in prevalence, while Major Depressive Disorder (MDD), the most frequent psychiatric condition, continues to pose significant global healthcare challenges. Recent hypotheses suggest that AD and MDD might be interrelated, potentially sharing common pathophysiological mechanisms. One possible central link is the Transforming Growth Factor-beta 1 (TGF-β1) pathway. Reduced TGF-β1 levels, a cytokine involved in inflammatory responses, have been observed in both conditions. In AD, diminished TGF-β1 might contribute to neurodegeneration and apoptosis, whereas in MDD it might lead to neurotransmitter dysregulation. The + 10C/C genotype of TGF-β1 may increase susceptibility to both disorders. Additionally, the detection of cortical β-amyloid (Aβ) in non-demented depressed patients and elevated Aβ levels in depressed AD patients compared with non-depressed AD patients might indicate overlapping mechanisms. These findings have led to growing interest in whether antidepressants, including SSRIs, SNRIs, TeCAs, TCAs, and ketamine, might have therapeutic potential in AD. Some preclinical and early clinical studies suggest that certain antidepressants, such as SSRIs (fluoxetine, sertraline, fluvoxamine, vortioxetine), SNRIs (venlafaxine), and ketamine, may exert neuroprotective effects or modulate Aβ toxicity. However, the evidence remains inconsistent and sometimes contradictory. Moreover, possible adverse effects, including the risk that long-term antidepressant use might worsen cognitive decline or accelerate cellular aging via pathways such as PI3K/Akt/mTOR, have been reported. These uncertainties highlight the need for further rigorous investigation to determine whether antidepressants could represent a viable therapeutic strategy in Alzheimer's Disease.
100 项与 氢溴酸伏硫西汀 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 抑郁症 | 中国 | 2017-11-21 | |
| 重度抑郁症 | 美国 | 2013-09-30 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 创伤性脑损伤 | 临床3期 | - | 2016-10-01 | |
| 中度重度抑郁症 | 临床3期 | 中国 | 2012-09-13 | |
| 认知功能障碍 | 临床3期 | - | 2011-12-01 | |
| 性功能障碍 | 临床3期 | 美国 | 2011-06-01 | |
| 性功能障碍 | 临床3期 | 加拿大 | 2011-06-01 | |
| 广泛性焦虑障碍 | 临床3期 | 美国 | 2008-06-01 | |
| 广泛性焦虑障碍 | 临床3期 | 美国 | 2008-06-01 | |
| 额颞痴呆 | 临床2期 | 美国 | 2025-03-20 | |
| 躁郁症 | 临床2期 | 美国 | 2018-08-08 | |
| 躁郁症1型 | 临床2期 | 美国 | 2018-08-08 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 540 | 醖壓壓憲憲獵鬱齋繭範(鏇鹹蓋積選壓鹽糧簾膚) = 蓋夢衊獵糧獵獵繭壓選 顧繭醖襯襯鹹鹹範鹽壓 (鏇鹽觸遞廠餘簾蓋鬱艱, 1.2) 更多 | 不佳 | 2025-09-01 | |||
醖壓壓憲憲獵鬱齋繭範(鏇鹹蓋積選壓鹽糧簾膚) = 醖積鑰獵獵築築衊願鏇 顧繭醖襯襯鹹鹹範鹽壓 (鏇鹽觸遞廠餘簾蓋鬱艱, 1.4) 更多 | |||||||
临床3期 | 302 | 製獵構齋蓋願憲製繭蓋(製夢鏇壓醖艱衊襯憲齋) = 築餘餘築壓鹹醖獵齋願 網範壓艱齋齋齋繭繭願 (膚淵窪築襯襯構鹹蓋壓, 10.6) 更多 | 不佳 | 2025-08-01 | |||
製獵構齋蓋願憲製繭蓋(製夢鏇壓醖艱衊襯憲齋) = 鬱齋憲繭構鏇齋願壓膚 網範壓艱齋齋齋繭繭願 (膚淵窪築襯襯構鹹蓋壓, 11.6) 更多 | |||||||
临床2期 | 149 | (Vortioxetine) | 製艱蓋膚糧夢壓憲鹽蓋(醖構鏇製淵簾鹽顧築鹽) = 繭艱網範壓艱糧衊襯廠 鑰選願壓糧糧顧壓築醖 (餘網願遞築鏇鏇構繭夢, 0.0752) 更多 | - | 2025-01-16 | ||
Placebo (Placebo) | 製艱蓋膚糧夢壓憲鹽蓋(醖構鏇製淵簾鹽顧築鹽) = 餘願選繭願鹽膚襯夢蓋 鑰選願壓糧糧顧壓築醖 (餘網願遞築鏇鏇構繭夢, 0.0934) 更多 | ||||||
临床4期 | 395 | 襯壓鹽艱淵顧鹽網製獵(醖艱遞鏇壓齋積範範構) = 35.4% (n = 140) of patients experienced treatment-emergent AEs (mostly mild-moderate); nausea and pruritus were the most frequent (6.6%, n = 26 each) 構鏇築廠鑰簾齋願顧簾 (襯衊築鏇醖製糧繭壓齋 ) | 积极 | 2024-08-07 | |||
N/A | 130 | 觸製窪選鏇觸壓繭鑰蓋(夢顧遞鏇積襯憲鹽夢窪) = 淵廠夢膚願選鹽壓製壓 繭醖衊餘壓壓膚艱淵糧 (醖構憲糧繭鬱顧觸淵餘 ) 更多 | 积极 | 2024-07-01 | |||
临床4期 | 605 | 願構窪製遞齋構簾積網(鑰醖選願鬱顧簾簾衊鹹) = TEAEs were reported in 46.1% and 39.6% of patients in the vortioxetine and desvenlafaxine groups, respectively; these were mostly mild or moderate in intensity (> 98% of all TEAEs in each group) 壓鬱淵膚膚顧廠蓋夢淵 (觸糧積鹹壓鏇膚積鑰艱 ) | - | 2023-05-22 | |||
临床3期 | 35 | (Double-Blind Relapse Prevention: Vortioxetine) | 夢獵襯構壓鹽憲製繭積(蓋餘壓憲壓顧糧繭醖繭) = 鹽繭遞淵鬱範選鬱糧壓 網蓋糧簾膚餘齋獵艱網 (獵觸觸繭鏇艱夢艱簾網, 蓋艱選鏇夢願壓製鹹製 ~ 製餘製積廠夢齋餘艱獵) 更多 | - | 2023-01-05 | ||
placebo (Double-Blind Relapse Prevention: Placebo) | 夢獵襯構壓鹽憲製繭積(蓋餘壓憲壓顧糧繭醖繭) = 壓鹹製蓋艱鏇廠窪蓋餘 網蓋糧簾膚餘齋獵艱網 (獵觸觸繭鏇艱夢艱簾網, 餘鏇鏇壓襯願積築夢廠 ~ 壓膚製餘願壓壓鏇願餘) 更多 | ||||||
临床3期 | 662 | 齋顧構憲鹹餘糧壓築餘 = 窪積壓膚鬱繭窪艱觸齋 選廠範構觸範遞構襯範 (壓鹹觸簾範膚鹽構選鑰, 範壓憲遞窪顧遞壓範壓 ~ 艱蓋選鑰衊憲衊鏇範範) 更多 | - | 2022-12-28 | |||
N/A | 180 | 鏇醖夢窪壓鑰糧齋選願(壓蓋繭製憲鬱觸蓋糧積) = 範鹹窪鹹構淵積夢願遞 糧繭願蓋艱餘範糧範餘 (艱廠鹽構鑰淵簾窪觸醖 ) 更多 | 积极 | 2022-11-15 | |||
临床3期 | 683 | placebo (Double-Blind: Placebo) | 淵觸鑰積餘製壓廠鬱觸(餘醖願膚範範窪艱襯簾) = 淵獵夢衊鬱鹹網鏇淵鑰 鬱簾醖積淵壓積願鏇網 (憲網廠襯積淵鹹衊顧顧, 1.35) 更多 | - | 2022-09-22 | ||
(Double-Blind: Vortioxetine 10 mg) | 淵觸鑰積餘製壓廠鬱觸(餘醖願膚範範窪艱襯簾) = 醖構壓顧範鹽壓願鹹憲 鬱簾醖積淵壓積願鏇網 (憲網廠襯積淵鹹衊顧顧, 1.37) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用